Introduction: We investigated the monopolar and bipolar energy effects on prostate and correlated the results with the type of pathology, thus determining the relationship between tissue damage and the PSA level. Material and Methods: One hundred and twenty four patients underwent TURP and according to the energy source, 2 groups were designed as monopolar (Group 1) and bipolar energy (Group 2). Hemoglobin and free and total PSA were measured preoperatively and 6 hours postoperatively, and differences were calculated. The weight of resected tissue and operation time were also recorded. Two groups were also formed later according to the pathology as chronic prostatitis (CP) and BPH. The findings were analyzed. Results: There were no statistical differences between the groups in terms of age; prostate volumes; resected tissue; operation times; pre- and postoperative Hb, total-free PSA, IPSS, PVR, and quality of life scores; or postoperative maximum flow rates. Changes in total-free PSA (25.7 and 10.8 ng/dl for PSA; 13.2 and 5.76 ng/dl for free PSA for Groups 1 and 2, respectively) were significantly different between Groups 1 and 2. There was a statistical difference in total PSA between the groups among CP patients (28.18 and 11.73 ng/dl for Groups 1 and 2, respectively). But no statistical difference existed among BPH patients. The change in Hb differed based on pathological results. Conclusion: Bipolar TURP is less invasive than monopolar TURP on the basis of postoperative PSA levels. In addition, bleeding during TURP is affected not by the kind of energy, but by the pathology.

Keywords:
Transurethral resection of prostate, Prostatic specific antigene, Chronic prostatitis, Benign prostate hyperplasia
1.
Bucuras V, Bardan R: Bipolar vaporization of the prostate: is it ready for the primetime? Ther Adv Urol 2011;3:257-261.
2.
Issa MM: Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP. J Endourol 2008;22:1587-1595.
3.
Thiel DD, Petrou SP: Electroresection and open surgery. Urol Clin North Am 2009;36:461-470, vi.
4.
Thomson RD, Clejan S: Digital rectal examination-associated alterations in serum prostate-specific antigen. Am J Clin Pathol 1992;97:528-534.
5.
Ko R, Tan AH, Chew BH, Rowe PE, Razvi H: Comparison of the thermal and histopathological effects of bipolar and monopolar electrosurgical resection of the prostate in a canine model. BJU Int 2010;105:1314-1317.
6.
Karaman MI, Kaya C, Ozturk M, Gurdal M, Kirecci S, Pirincci N: Comparison of transurethral vaporization using PlasmaKinetic energy and transurethral resection of prostate: 1-year follow-up. J Endourol 2005;19:734-737.
7.
Huang X, Wang XH, Qu LJ, Pu XY, Zeng X: Bipolar versus monopolar transurethral resection of prostate: pathologic study in canines. Urology 2007;70:180-184.
8.
Akman T, Binbay M, Tekinarslan E, Tepeler A, Akcay M, Ozgor F, Ugurlu M, Muslumanoglu A: Effects of bipolar and monopolar transurethral resection of the prostate on urinary and erectile function: a prospective randomized comparative study. BJU Int 2013;111:129-136.
9.
Singh H, Desai MR, Shrivastav P, Vani K: Bipolar versus monopolar transurethral resection of prostate: randomized controlled study. J Endourol 2005;19:333-338.
10.
Mamoulakis C, Skolarikos A, Schulze M, Scoffone CM, Rassweiler JJ, Alivizatos G, Scarpa RM, de la Rosette JJ: Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting. BJU Int 2013;112:109-120.
11.
Mamoulakis C, Schulze M, Skolarikos A, Alivizatos G, Scarpa RM, Rassweiler JJ, de la Rosette JJ, Scoffone CM: Midterm results from an international multicentre randomised controlled trial comparing bipolar with monopolar transurethral resection of the prostate. Eur Urol 2013;63:667-676.
12.
Autorino R, Damiano R, Di Lorenzo G, Quarto G, Perdonà S, D'Armiento M, De Sio M: Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol 2009;55:922-929.
13.
Karadag MA, Cecen K, Demir A, Kocaaslan R, Altunrende F: Plasmakinetic vaporization versus plasmakinetic resection to treat benign prostatic hyperplasia: a prospective randomized trial with 1 year follow-up. Can Urol Assoc J 2014;8:E595-E599.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.